RAMP is leading industry transformation towards responsible antibiotics manufacturing to reduce the spread of antimicrobial resistance.

The Responsible Antibiotics Manufacturing Platform, RAMP, is operating to create new incentives based on criteria that define responsible manufacturing. Pioneers from the antibiotics manufacturing industry have joined forces with the most forward-thinking buyers and regulators to reduce emissions from antibiotics production. All stakeholders contribute to jointly define higher standards for reducing emissions that are verified, demand-driven and scientifically sound.

The release of antibiotics from manufacturing waste streams into the environment poses global health and business risks. Yet, it remains a challenge to bring about change for two reasons. First, there is a lack of jointly defined objectives and access to verified information that shows progress towards reduction in antimicrobial resistance. Second, there is a lack of enabling conditions that drive demand and incentivise improved industry practice.

 

Since 2021
Global
RAMP logo: a circle with 2 tones of blue feeding into each other

Responsible Antibiotics Manufacturing Platform

RAMP turns prevention of antibiotics manufacturing emissions into a business objective.

About RAMP
RAMP is led by SIWI in partnership with
Shawview Consulting
Shawview Consulting
swiss_logo
Swiss Agency for Development and Cooperation (SDC)
Centrient Pharmaceuticals
Centrient Pharmaceuticals
GlaxoSmithKline
GlaxoSmithKline (GSK)
Novartis
Novartis
sandoz-vector-logo
Sandoz
AMR Industry logo with coloured bubbles
AMR Industry Alliance (Technical partner)
A purple gradient through capital letters SPANS, where the A is in the shape of a triangle.
SPANS